PolyPid Reports Growth in Mid-Year Assets

PolyPid (PYPD) has released an update.

PolyPid Ltd., a pharmaceutical company, has reported its interim condensed consolidated financial statements for the period ending June 30, 2024. The unaudited report highlights a total asset increase to $19,527 thousand from $15,372 thousand at the end of the previous year. Additionally, the company shows a shareholders’ equity of $1,601 thousand, recovering from a deficit position.

For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.